Home

Qingsong ‘Jet’ Li founded ImmuneSensor in 2014 and is the Interim CEO of the company. Before coming to the U.S. in 1998, he co-founded Longstar Lighting, a leading manufacturer and supplier of energy-saving lighting products to global customers. He previously worked in sales for Sinochem, one of the largest oil and energy service providers in China. Mr. Li is actively involved in community service and has been a volunteer and supporter for the Overseas Chinese Education Foundation for many years. He serves on the board of directors of the Crow Museum of Asian Art of The University of Texas at Dallas and is a trustee of the board of the Greenhill School, also in Dallas. Mr. Li received a bachelor’s degree in International Business from Guangdong University of Foreign Studies and an M.B.A and Master’s degree in Information Systems from the University of Texas at Arlington.

Close

Edward Garmey is a former academic hematologist-oncologist, and has served as Chief Medical Officer for several private and public biopharmaceutical companies during his 15 years in industry. Dr. Garmey served as Chief Medical Officer and Senior Vice President at Cerulean Pharma, where he oversaw the initiation of multi-national clinical trials for multiple drug programs and helped lead the company’s successful $67 MM IPO. Previously, Dr. Garmey served as a pediatric hematologist-oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). He is an alumnus of Harvard and New York University and completed his medical training at New York’s Mount Sinai Medical Center, the Children’s Hospital of Los Angeles and MSKCC. Dr. Garmey completed additional research fellowships at the National Institutes of Health and the Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana and is the recipient of the young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey currently resides in the Boston area, where he serves as an adjunct instructor at Harvard Medical School’s Graduate Program in Therapeutic Science and as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.

Close

Teresa Mooneyham has extensive experience in the healthcare and life science industries, with 39 years in nursing including over 26 years in clinical research. Prior to joining ImmuneSensor, Ms. Mooneyham served as Director of Project Management at Sarah Cannon Development Innovations. Previously, she served as Senior Director of Project Management at Chiltern (formerly Ockham Oncology/Nexus Oncology). Throughout her career, she has held various roles within clinical operations and project management including Research Nurse, Clinical Research Associate (CRA), Clinical Manager, Project Manager/Director, Senior Director of Project Management and Director of Clinical Operations. Ms. Mooneyham has also been responsible for department oversight within project management and has served as trainer and mentor to project management and clinical operations staff. Additionally, she has supported efforts in the submission of two oncology NDAs.

Close

Lijun “Josh” Sun has more than 15 years of experience leading critical research of the innate immune system, including the RIG-I-MAVS and cGAS-STING pathways. Notably, he co-discovered cyclic GMP-AMP (cGAMP) and its synthase cGAS, which laid the foundation for therapeutics development at ImmuneSensor. As Director of Biology, Dr. Sun oversees the development of STING agonists for cancer immunotherapy as well as antagonists targeting innate immunity signaling pathways for the treatment of autoimmune and inflammatory diseases. Prior to joining ImmuneSensor in 2018, Dr. Sun served as an Associate Professor at UT Southwestern Medical Center and as a Research Specialist at Howard Hughes Medical Institute.

Close

Jian Qiu joined ImmuneSensor in April 2017 as Director of Chemistry. He has more than 20 years of experience in drug discovery and development and currently manages the medicinal chemistry and CMC functions at ImmuneSensor. Before joining the company, Dr. Qiu held scientific research and management positions at Dharmacon, Invenux, Replidyne and Nivalis Therapeutics. Dr. Qiu received his B.S. and M.S. in organic chemistry from Nankai University and his Ph.D. in organic chemistry from Cambridge University.

Close